Net cash use in operations for second half 2023 is expected to be $40 to $50 million, consistent with previous guidance and driven primarily by expenses for our clinical program in Alzheimer’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SAVA:
- Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
- Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
- Cassava Sciences completes patient enrollment for Phase 3 program of simufilam
- Cassava Sciences put volume heavy and directionally bearish
- Largest borrow rate increases among liquid names